Idera shares slide on PhII fail­ure; WuXi blue­prints $60M man­u­fac­tur­ing cen­ter in Worces­ter, MA

→ Shares of Idera Phar­ma­ceu­ti­cals $IDRA were ham­mered ear­ly to­day af­ter the biotech re­port­ed that their Phase II clin­i­cal tri­al of IMO-8400 in adult pa­tients with der­mato­myosi­tis failed. The study re­cruit­ed on­ly 30 pa­tients, di­vid­ing them in­to one of three dosage groups for up to 24 weeks. The stock ini­tial­ly plunged close to 30%, but then pulled back from the brink, down about 12% in ear­ly trad­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER